Extraintestinale Manifestationen chronisch entzündlicher Darmerkrankungen

Verena von Felbert; Thomas Rauen; Stefanie Tischendorf; Maximilian Hatting

doi:10.1055/a-1290-2546

Der Klinikarzt, Inhaltsverzeichnis

Der Klinikarzt 2020; 49(12): 530-537
DOI: 10.1055/a-1290-2546

Schwerpunkt

Extraintestinale Manifestationen chronisch entzündlicher Darmerkrankungen

Fokus auf Gelenke und Haut

Verena von Felbert

¹Klinik für Dermatologie und Allergologie, Hautklinik Universitätsklinikum Aachen

,

Thomas Rauen

²Sektion Rheumatologie in der Klinik für Nieren- und Hochdruckkrankheiten, rheumatologische und immunologische Erkrankungen (Medizinische Klinik II), Universitätsklinikum Aachen

,

Stefanie Tischendorf

³Klinik für Gastroenterologie, Stoffwechselerkrankungen und Internistische Intensivmedizin (Medizinische Klinik III), Universitätsklinikum Aachen

,

Maximilian Hatting

³Klinik für Gastroenterologie, Stoffwechselerkrankungen und Internistische Intensivmedizin (Medizinische Klinik III), Universitätsklinikum Aachen

› Institutsangaben

Abstract

ZUSAMMENFASSUNG

Chronisch entzündliche Darmerkrankungen (CED) manifestieren sich auch außerhalb des Gastrointestinaltraktes. Die Differenzialdiagnostik ist herausfordernd, denn die extraintestinalen Manifestationen (EIM) müssen von Medikamentennebenwirkungen und eigenständigen Krankheitsentitäten abgegrenzt werden. Dies trifft insbesondere für den Befall der Leber, des Bewegungsapparates und der Haut zu. Häufig sind Leberwerterhöhungen medikamentös-toxisch bedingt. Die primär sklerosierende Cholangitis stellt eine prognoserelevante Differenzialdiagnose dar, die häufig mit CED assoziiert ist. Ein Befall des Achsenskeletts muss von degenerativem Rückenschmerz, Osteoporose und einer rheumatischen Grunderkrankung abgegrenzt werden. Die Beteiligung der Haut bei CED kann sich im Rahmen klassischer Befunde wie dem Erythema nodosum manifestieren. Häufig ist die Diagnosestellung aber schwierig und es müssen medikamenteninduzierte Hautveränderungen ausgeschlossen bzw. identifiziert werden. Nicht zuletzt ist auch das Risiko für Hauttumoren unter Immunsuppression erhöht. Die komplexe Diagnostik der extraintestinalen Manifestation erfordert deshalb eine enge interdisziplinäre Zusammenarbeit.

Volltext

Referenzen

Literatur
1 Vavricka SR, Rogler G, Gantenbein C. et al Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort. Inflamm Bowel Dis 2015; 21: 1794-1800
2 Mendoza JL, Lana R, Taxonera C. et al Manifestaciones extraintestinales en la enfermedad inflamatoria intestinal: diferencias entre la enfermedad de Crohn y la colitis ulcerosa. Medicina clinica 2005; 125: 297-300
3 Herfarth H, Obermeier F, Andus T. et al Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn’s disease. Am J Gastroenterol 2002; 97: 2688-2690
4 Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol 1996; 23: 29-34
5 Vind I, Riis L, Jess T. et al Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003–2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol 2006; 101: 1274-1282
6 Bernstein CN, Blanchard JF, Rawsthorne P. et al The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 2001; 96: 1116-1122
7 Vavricka SR, Schoepfer A, Scharl M. et al Extraintestinal Manifestations of Inflammatory Bowel Disease. Inflamm Bowel Dis 2015; 21: 1982-1992
8 Larsen S, Bendtzen K, Nielsen OH. Extraintestinal manifestations of inflammatory bowel disease: epidemiology, diagnosis, and management. Ann Med 2010; 42: 97-114
9 Ernst BB, Lowder CY, Meisler DM. et al Posterior Segment Manifestations of inflammatory Bowel Disease. Ophthalmology 1991; 98: 1272-1280
10 Falavarjani KG, Parvaresh MM, Shahraki K. et al Central retinal artery occlusion in Crohn disease. J AAPOS 2012; 16: 392-393
11 Felekis T, Katsanos KH, Zois CD. et al Anterior ischemic optic neuropathy in a patient with Crohn’s disease and aberrant MTHFR and GPIIIa gene variants. J Crohns Colitis 2010; 4: 471-474
12 Mintz R, Feller ER, Bahr RL. et al Ocular manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 135-139
13 Lyons JL, Rosenbaum JT. Uveitis associated with inflammatory bowel disease compared with uveitis associated with spondyloarthropathy. Arch Ophthalmol 1997; 115: 61-64
14 Calvo P, Pablo L. Managing IBD outside the gut: ocular manifestations. Dig Dis 2013; 31: 229-232
15 Sharma SM, Nestel AR, Lee RWJ. et al Clinical review: Anti-TNFalpha therapies in uveitis: perspective on 5 years of clinical experience. Ocul Immunol Inflamm 2009; 17: 403-414
16 Imrie FR, Dick AD. Biologics in the treatment of uveitis. Curr Opin Ophthalmol 2007; 18: 481-486
17 Levy-Clarke G, Jabs DA, Read RW. et al Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 2014; 121: 785-796.e3
18 Mendes FD, Levy C, Enders FB. et al Abnormal hepatic biochemistries in patients with inflammatory bowel disease. Am J Gastroenterol 2007; 102: 344-350
19 Schrumpf E, Fausa O, Elgjo K. et al Hepatobiliary complications of inflammatory bowel disease. Semin Liver Dis 1988; 8: 201-209
20 Fausa O, Schrumpf E, Elgjo K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin Liver Dis 1991; 11: 31-39
21 Schrumpf E, Boberg KM. Epidemiology of primary sclerosing cholangitis. Best Prac Res Clin Gastroenterol 2001; 15: 553-562
22 Broomé U, Bergquist A. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin Liver Dis 2006; 26: 31-41
23 Claessen MMH, Lutgens MWMD, van Buuren HR. et al More right-sided IBD-associated colorectal cancer in patients with primary sclerosing cholangitis. Inflamm Bowel Dis 2009; 15: 1331-1336
24 Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. Journal of hepatology 2012; 56: 1181-1188
25 Dourakis SP, Sevastianos VA, Kaliopi P. Acute severe steatohepatitis related to prednisolone therapy. Am J Gastroenterol 2002; 97: 1074-1075
26 Candelli M, Nista EC, Pignataro G. et al Steatohepatitis during methylprednisolone therapy for ulcerative colitis exacerbation. J Intern Med 2003; 253: 391-392
27 Khokhar OS, Lewis JH. Hepatotoxicity of agents used in the management of inflammatory bowel disease. Dig Dis 2010; 28: 508-518
28 Khan N, Abbas AM, Whang N. et al Incidence of liver toxicity in inflammatory bowel disease patients treated with methotrexate: a meta-analysis of clinical trials. Inflamm Bowel Dis 2012; 18: 359-367
29 Gisbert JP, González-Lama Y, Maté J. Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. Am J Gastroenterol 2007; 102: 1518-1527
30 Ghabril M, Bonkovsky HL, Kum C. et al Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol 2013; 11: 558-564.e3
31 Musumba CO. Review article: the association between nodular regenerative hyperplasia, inflammatory bowel disease and thiopurine therapy. Aliment Pharmacol Ther 2013; 38: 1025-1037
32 Remzi FH, Fazio VW, Oncel M. et al Portal vein thrombi after restorative proctocolectomy. Surgery 2002; 132: 655-661
33 Greenstein AJ, Sachar DB, Panday AK. et al Amyloidosis and inflammatory bowel disease. A 50-year experience with 25 patients. Medicine 1992; 71: 261-270
34 Tofteland ND, Nassif II. Abnormal liver enzymes in a patient with Crohn’s disease, psoriatic arthritis, and recurrent pancreatitis. Answer to the clinical challenges and images in GI question: image 5: Idiopathic granulomatous hepatitis. Gastroenterology 2010; 139: e14-e15
35 Bermejo F, Lopez-Sanroman A, Taxonera C. et al Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis. Aliment Pharmacol Ther 2008; 28: 623-628
36 Moolsintong P, Loftus EV, Chari ST. et al Acute pancreatitis in patients with Crohn’s disease: clinical features and outcomes. Inflamm Bowel Dis 2005; 11: 1080-1084
37 Parente F, Pastore L, Bargiggia S. et al Incidence and risk factors for gallstones in patients with inflammatory bowel disease: a large case-control study. Hepatology 2007; 45: 1267-1274
38 Haber CJ, Meltzer SJ, Present DH. et al Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease. Gastroenterology 1986; 91: 982-986
39 Present DH, Meltzer SJ, Krumholz MP. et al 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989; 111: 641-649
40 Weber P, Seibold F, Jenss H. Acute pancreatitis in Crohn’s disease. J Clin Gastroenterol 1993; 17: 286-291
41 Rasmussen HH, Fonager K, Sørensen HT. et al Risk of acute pancreatitis in patients with chronic inflammatory bowel disease. A Danish 16-year nationwide follow-up study. Scand J Gastroenterol 1999; 34: 199-201
42 Munk EM, Pedersen L, Floyd A. et al Inflammatory bowel diseases, 5-aminosalicylic acid and sulfasalazine treatment and risk of acute pancreatitis: a population-based case-control study. Am J Gastroenterol 2004; 99: 884-888
43 Kristensen SL, Ahlehoff O, Lindhardsen J. et al Disease activity in inflammatory bowel disease is associated with increased risk of myocardial infarction, stroke and cardiovascular death – a Danish nationwide cohort study. PloS one 2013; 8: e56944
44 Jussila A, Virta LJ, Pukkala E. et al Mortality and causes of death in patients with inflammatory bowel disease: a nationwide register study in Finland. J Crohns Colitis 2014; 8: 1088-1096
45 Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695
46 Cao JJ, Arnold AM, Manolio TA. et al Association of carotid artery intima-media thickness, plaques, and C-reactive protein with future cardiovascular disease and all-cause mortality: the Cardiovascular Health Study. Circulation 2007; 116: 32-38
47 Tan VP, Chung A, Yan BP. et al Venous and arterial disease in inflammatory bowel disease. J Gastroenterol Hepatol 2013; 28: 1095-1113
48 Rungoe C, Basit S, Ranthe MF. et al Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study. Gut 2013; 62: 689-694
49 Storch I, Sachar D, Katz S. Pulmonary manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2003; 9: 104-115
50 Fiorino G, Danese S, Pariente B. et al Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-α agents. Autoimmun Rev 2014; 13: 15-19
51 Ekbom A, Brandt L, Granath F. et al Increased risk of both ulcerative colitis and Crohn’s disease in a population suffering from COPD. Lung 2008; 186: 167-172
52 Yuhara H, Steinmaus C, Corley D. et al Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013; 37: 953-962
53 Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008; 103: 2272-2280
54 Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 2010; 375: 657-663
55 Scoville EA, Konijeti GG, Nguyen DD. et al Venous thromboembolism in patients with inflammatory bowel diseases: a case-control study of risk factors. Inflamm Bowel Dis 2014; 20: 631-636
56 Papay P, Miehsler W, Tilg H. et al Clinical presentation of venous thromboembolism in inflammatory bowel disease. J Crohns Colitis 2013; 7: 723-729
57 Johannesdottir SA, Horváth-Puhó E, Dekkers OM. et al Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. JAMA 2013; 173: 743-752
58 Harbord M, Annese V, Vavricka SR. et al The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. J Crohns Colitis 2016; 10: 239-254
59 Salvarani C, Vlachonikolis IG, van der Heijde DM. et al Musculoskeletal manifestations in a population-based cohort of inflammatory bowel disease patients. Scand J Gastroenterol 2001; 36: 1307-1313
60 Turkçapar N, Olmez U, Tutkak H. et al The importance of alpha-fodrin antibodies in the diagnosis of Sjögren’s syndrome. Rheumatol Int 2006; 26: 354-359
61 Blumberg BS, Bunim JJ, Calkins E. et al Ara Nomenclature and Classification of Arthritis and Rheumatism (TENTATIVE). Arthritis Rheum 1964; 7: 93-97
62 Sieper J, Braun J, Rudwaleit M. et al Ankylosing spondylitis: an overview. Ann Rheum Dis 2002; 61 (Suppl. 03) iii8-18
63 Peluso R, Di Minno MND, Iervolino S. et al Enteropathic spondyloarthritis: from diagnosis to treatment. Clin Dev Immunol 2013; 2013: 631408
64 Felice C, Leccese P, Scudeller L. et al Red flags for appropriate referral to the gastroenterologist and the rheumatologist of patients with inflammatory bowel disease and spondyloarthritis. Clin Exp Immunol 2019; 196: 123-138
65 Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn’s disease and ulcerative colitis: a study of 700 patients. Medicine 1976; 55: 401-412
66 Ploysangam T, Heubi JE, Eisen D. et al Cutaneous Crohn’s disease in children. J Am Acad Dermatol 1997; 36: 697-704
67 Fu Y, Lee C-H, Chi C-C. Association of Psoriasis With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. JAMA Dermatol 2018; 154: 1417-1423
68 Sy A, Khalidi N, Dehghan N. et al Vasculitis in patients with inflammatory bowel diseases: A study of 32 patients and systematic review of the literature. Semin Arthritis Rheum 2016; 45: 475-482
69 Ainley CC, Cason J, Carlsson LK. et al Zinc status in inflammatory bowel disease. Clin Sci (Lond) 1988; 75: 277-283
70 Nigam GB, Bhandare AP, Antoniou GA. et al Systematic review and meta-analysis of dermatological reactions in patients with inflammatory bowel disease treated with anti-tumour necrosis factor therapy. Eur J Gastroenterol Hepatol 2020
71 Li SJ, Perez-Chada LM, Merola JF. TNF Inhibitor-Induced Psoriasis: Proposed Algorithm for Treatment and Management. J Psoriasis Psoriatic Arthritis 2019; 4: 70-80
72 Lo B, Zhao M, Vind I. et al The Risk of Extraintestinal Cancer in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Population-Based Cohort Studies. Clin Gastroenterol Hepatol 2020
73 Giagkou E, Saridi M, Albani E. et al Dermal Lesions and Skin Cancer in Patients with Inflammatory Bowel Disease Receiving Immunosuppressive Therapy. Asian Pac J Cancer Prev 2018; 19: 2845-2851
74 Dahmus J, Rosario M, Clarke K. Risk of Lymphoma Associated with Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: Implications for Therapy. Clin Exp Gastroenterol 2020; 13: 339-350